Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Celltrion, Inc.
  6. News
  7. Summary
    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report
End-of-day quote Korea Stock Exchange  -  2022-08-09
211500.00 KRW    0.00%
08/09Celltrion Files IND With FDA For Adalimumab Biosimilar
AQ
08/07Celltrion's Net Income Jumps 41.2% in June Quarter
MT
08/05S.Korean shares post third straight weekly gain
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Celltrion, Inc. authorizes a Buyback Plan.

05/18/2022 EDT
share with twitter
share with LinkedIn
share with facebook

The Board of Directors of Celltrion, Inc. has authorized a buyback plan on May 18, 2022.


© S&P Capital IQ 2022
All news about CELLTRION, INC.
08/09Celltrion Files IND With FDA For Adalimumab Biosimilar
AQ
08/07Celltrion's Net Income Jumps 41.2% in June Quarter
MT
08/05S.Korean shares post third straight weekly gain
RE
08/05CELLTRION : 2Q 2022 Earnings Release_Celltrion Inc.
PU
07/26Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on May 18, 2022.
CI
07/26Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on May 18, 2022.
CI
07/22Celltrion, Inc.'s Equity Buyback announced on May 18, 2022, has closed with 500,000 sha..
CI
07/19Hikma and Celltrion sign exclusive licensing agreement for YuflymaTM for the Middle Eas..
AQ
06/26Celltrion Wins Sales Approval Recommendation For Its CT-P16 From European Medicines Age..
RE
06/06Celltrion Eyes to Boost Market Share in Europe of Rheumatoid Arthritis Medication to 50..
MT
More news
Analyst Recommendations on CELLTRION, INC.
More recommendations
Financials
Sales 2022 2 256 B 1,74 B 1,74 B
Net income 2022 601 B 0,46 B 0,46 B
Net cash 2022 681 B 0,52 B 0,52 B
P/E ratio 2022 49,3x
Yield 2022 0,19%
Capitalization 29 135 B 22 444 M 22 444 M
EV / Sales 2022 12,6x
EV / Sales 2023 11,4x
Nbr of Employees 2 034
Free-Float 75,0%
Chart CELLTRION, INC.
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLTRION, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 211 500,00 KRW
Average target price 218 060,78 KRW
Spread / Average Target 3,10%
EPS Revisions
Managers and Directors
Wu-Sung Ki Chief Executive Officer & Director
Ho-Seop Lee Finance Director
Jung-Jin Seo Chairman
Sung-Han Lee Head-Legal & Compliance Support
Dong-Il Kim Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CELLTRION, INC.6.82%22 444
MODERNA, INC.-31.38%68 174
LONZA GROUP AG-26.76%44 940
IQVIA HOLDINGS INC.-15.05%44 704
SEAGEN INC.13.62%32 396
ALNYLAM PHARMACEUTICALS, INC.36.81%27 846